AstraZeneca EBIT/Varat

Mitä AstraZeneca tekee? AstraZeneca PLC generates revenue through the sale of prescription medicines including Imjudo, Tagrisso, Lynparza, and Enhertu, which target oncology and respiratory conditions. The company markets products like Crestor for cardiovascular health and Farxiga/Forxiga for renal and metabolic diseases, sold to healthcare providers and patients globally. Brands such as Imfinzi and Orpathys are distributed through pharmaceutical distributors and hospitals, while vaccines like Beyfortus and Evusheld cater to public health programs. AstraZeneca’s portfolio includes respiratory treatments like Symbicort Turbuhaler and immunology drugs such as Tezspire, serving segments in respiratory & immunology and oncology. The company monetizes through branded prescription drugs including Iressa for lung cancer, Brilinta/Brilique for cardiovascular care, and Zoladex for hormone therapy, sold to hospitals and clinics. Products like Onglyza and XIGDUO XR target metabolic and cardiovascular markets, purchased by patients and insurers. AstraZeneca’s respiratory portfolio features Pulmicort Turbuhaler and Bevespi Aerosphere, marketed to respiratory specialists and hospitals. Vaccines such as Fluenz/FluMist and Synagis are sold to government health agencies for public immunization programs. AstraZeneca’s revenue streams include oncology drugs like Calquence and Tagrisso, sold to cancer centers and hospitals, and cardiovascular medicines such as Atacand HCT and Tenormin, distributed to pharmacies and clinics. Respiratory treatments like Airsupra and Saphnelo target chronic respiratory conditions, purchased by healthcare providers. The company’s immunology segment features drugs like Fasenra and Rhinocort, sold to allergy specialists and hospitals. Vaccines including Kavigale and Ultomiris are supplied to public health initiatives for respiratory and rare disease management. AstraZeneca on yksi Eurpooliin suosituimmista yhtiöistä.